PDGFRB and chronic myelogenous leukemia, BCR-ABL1 positive: In CML, TKIs such as imatinib and dasatinib, have been shown to not only target and inhibit BCR-ABL1, but also c-KIT, PDGF receptor (PDGFR), and Src family kinases, which results in the abrogation of the transcription of pro-inflammatory cytokines such as IL-1, IL-6, and TNF-α, and prevents the proliferation of myeloid cells (70).